Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization
Vivos Inc (OTCQB: RDGL) has filed a provisional patent (No. 63/873,014) for a new electron beam (E-Beam) sterilization process for their hydrogel technology. The process, validated under ISO 11137, achieves a sterility assurance level of 10-6 - the highest standard for critical medical devices.
The new sterilization method offers significant advantages over their current filtration process, including improved reliability, cost-effectiveness, and enhanced scalability. This advancement benefits both their Radiogel® (human) and IsoPet® (animal) therapy product lines, positioning the company for broader market penetration and increased revenue opportunities.
Vivos Inc (OTCQB: RDGL) ha depositato un brevetto provvisorio (n. 63/873.014) per un nuovo processo di sterilizzazione mediante fascio di elettroni (E-Beam) applicato alla sua tecnologia idrogel. Il processo, convalidato secondo la norma ISO 11137, raggiunge un livello di garanzia di sterilità di 10^-6 — il più alto standard per dispositivi medici critici.
Il nuovo metodo di sterilizzazione presenta vantaggi significativi rispetto al processo di filtrazione attuale, tra cui maggiore affidabilità, convenienza economica e migliore scalabilità. Questo progresso avvantaggia sia le linee di terapia Radiogel® (uso umano) sia IsoPet® (uso veterinario), posizionando l’azienda per una più ampia penetrazione del mercato e maggiori opportunità di ricavo.
Vivos Inc (OTCQB: RDGL) ha presentado una solicitud de patente provisional (n. 63/873,014) para un nuevo proceso de esterilización por haz de electrones (E-Beam) para su tecnología de hidrogel. El proceso, validado conforme a la norma ISO 11137, alcanza un nivel de garantía de esterilidad de 10^-6, el estándar más alto para dispositivos médicos críticos.
El nuevo método de esterilización ofrece ventajas significativas frente a su proceso de filtración actual, incluyendo mayor fiabilidad, rentabilidad y mejor escalabilidad. Este avance beneficia tanto a sus líneas terapéuticas Radiogel® (uso humano) como IsoPet® (uso animal), posicionando a la empresa para una mayor penetración en el mercado y mayores oportunidades de ingresos.
Vivos Inc (OTCQB: RDGL)는 하이드로젤 기술을 위한 새로운 전자빔(E-Beam) 멸균 공정에 대해 임시 특허(번호 63/873,014)를 출원했습니다. 이 공정은 ISO 11137에 따라 검증되었으며, 중요 의료기기에 대한 최고 기준인 멸균 보증 수준 10^-6을 달성합니다.
새 멸균 방법은 현재의 여과 공정에 비해 신뢰성 향상, 비용 효율성, 확장성 증대 등 중요한 이점을 제공합니다. 이 진전은 Radiogel®(인체용)과 IsoPet®(동물용) 치료 제품군 모두에 이익이 되어 회사의 시장 확장과 수익 기회 증대에 기여할 것입니다.
Vivos Inc (OTCQB: RDGL) a déposé un brevet provisoire (n° 63/873,014) pour un nouveau procédé de stérilisation par faisceau d'électrons (E-Beam) appliqué à sa technologie d'hydrogel. Le procédé, validé selon la norme ISO 11137, atteint un niveau d'assurance de stérilité de 10^-6 — la norme la plus élevée pour les dispositifs médicaux critiques.
La nouvelle méthode de stérilisation présente des avantages significatifs par rapport à leur procédé de filtration actuel, notamment une fiabilité accrue, une meilleure rentabilité et une scalabilité améliorée. Cette avancée profite à la fois aux gammes thérapeutiques Radiogel® (usage humain) et IsoPet® (usage animal), positionnant la société pour une pénétration de marché plus large et des opportunités de revenus accrues.
Vivos Inc (OTCQB: RDGL) hat eine vorläufige Patentanmeldung (Nr. 63/873.014) für ein neues Elektronenstrahl-(E-Beam)-Sterilisationsverfahren für seine Hydrogel-Technologie eingereicht. Das Verfahren, validiert nach ISO 11137, erreicht ein Sterilisationssicherheitsniveau von 10^-6 – den höchsten Standard für kritische Medizinprodukte.
Das neue Sterilisationsverfahren bietet gegenüber dem bisherigen Filtrationsverfahren erhebliche Vorteile, darunter verbesserte Zuverlässigkeit, Kosteneffizienz und bessere Skalierbarkeit. Dieser Fortschritt kommt sowohl der Radiogel® (für Menschen) als auch der IsoPet® (für Tiere) Produktlinie zugute und positioniert das Unternehmen für eine breitere Marktdurchdringung und erhöhte Umsatzchancen.
- Achievement of 10-6 sterility assurance level, the highest standard for critical medical devices
- New process is more cost-effective and improves production yield compared to current filtration method
- Enhanced scalability for commercial growth and worldwide distribution
- Patent filing provides intellectual property protection
- Process benefits both human (Radiogel®) and animal (IsoPet®) therapy divisions
- None.
Kennewick, WA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc filed a provisional patent No.: 63/873,014 - STERILE THERMOGELS
Vivos Inc. is pleased to announce the successful validation of a new electron beam (E-Beam) sterilization process for our hydrogel, marking a culmination of nearly a year of testing and validation of a process that was only viable because of the unique characteristics of our hydrogel. The validation was carried out under ISO 11137 by an international medical device accredited organization. Vivos applies these same high standards to both human (Radiogel®) and animal (Isopet®) therapies.
The E-Beam sterilization process is reproduceable and more reliable than our current filtration process, achieving a sterility assurance level of 10-6, which is the most rigorous sterility level; meaning there is a one in a million chance of a viable microorganism surviving, and it is the standard for critical medical devices that enter the body or compromised tissues, ensuring patient safety by minimizing infection risk.
Beyond the clinical advantages, the process is more cost-effective, improves production yield, and meaningfully enhances scalability as we prepare for commercial growth. The ability to efficiently produce and distribute sterile hydrogel and PrecisionGel for therapeutic agent dispersal worldwide, supports Vivos’ strategic path toward broader market penetration.
Importantly, the process will also drive greater manufacturing efficiency for IsoPet®, our animal health therapy, enabling more consistent supply and cost-effective production to meet growing veterinary demand. This dual benefit—advancing both human and animal health divisions—positions Vivos for stronger revenue opportunities while reinforcing our competitive differentiator through intellectual property protection.
Michael K. Korenko, Sc.D.
President & CEO, Vivos Inc.
Email: MKorenko@RadioGel.com
Follow Vivos Inc. on X (Twitter): @VivosIncUSA
Learn more about RadioGel® and IsoPet® at www.VivosInc.com
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, identified by terms such as “will,” “expects,” “plans,” “anticipates,” and “intends.” These statements involve risks and uncertainties that may cause actual results to differ materially, including challenges in executing business strategies, economic conditions, competition, regulatory changes, delays in clinic certifications, and other factors beyond Vivos Inc.’s control. For a detailed discussion of these risks, refer to the company’s filings with the Securities and Exchange Commission.
FAQ
What is the significance of Vivos Inc's (RDGL) new E-Beam sterilization patent?
How does the new sterilization process benefit RDGL's business operations?
What sterility assurance level does Vivos's new E-Beam process achieve?
Which Vivos Inc products will benefit from the new E-Beam sterilization process?
What is the patent number for Vivos's new sterilization technology?
